X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Aventis Pharma with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs MYLAN (US) - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SANOFI INDIA   MYLAN
EQUITY SHARE DATA
    SANOFI INDIA
Dec-17
MYLAN
Dec-14
SANOFI INDIA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs4,9454,298-   
Low Rs3,9013,029-   
Sales per share (Unadj.) Rs1,081.81,471.5-  
Earnings per share (Unadj.) Rs141.6177.3-  
Cash flow per share (Unadj.) Rs185.9285.3-  
Dividends per share (Unadj.) Rs33.000-  
Dividend yield (eoy) %0.70-  
Book value per share (Unadj.) Rs868.8731.5-  
Shares outstanding (eoy) m23.03378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x4.12.5 164.2%   
Avg P/E ratio x31.220.7 151.2%  
P/CF ratio (eoy) x23.812.8 185.3%  
Price / Book Value ratio x5.15.0 101.6%  
Dividend payout %23.30-   
Avg Mkt Cap Rs m101,8621,386,233 7.3%   
No. of employees `0003.225.0 13.0%   
Total wages/salary Rs m3,6850-   
Avg. sales/employee Rs Th7,691.922,270.7 34.5%   
Avg. wages/employee Rs Th1,137.70-   
Avg. net profit/employee Rs Th1,006.52,682.9 37.5%   
INCOME DATA
Net Sales Rs m24,914556,766 4.5%  
Other income Rs m807-3,245 -24.9%   
Total revenues Rs m25,721553,521 4.6%   
Gross profit Rs m5,372138,470 3.9%  
Depreciation Rs m1,02240,892 2.5%   
Interest Rs m1124,016 0.0%   
Profit before tax Rs m5,14670,317 7.3%   
Minority Interest Rs m0-288 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,8862,957 63.8%   
Profit after tax Rs m3,26067,072 4.9%  
Gross profit margin %21.624.9 86.7%  
Effective tax rate %36.64.2 871.6%   
Net profit margin %13.112.0 108.6%  
BALANCE SHEET DATA
Current assets Rs m14,432489,471 2.9%   
Current liabilities Rs m6,010382,669 1.6%   
Net working cap to sales %33.819.2 176.2%  
Current ratio x2.41.3 187.7%  
Inventory Days Days6178 78.0%  
Debtors Days Days28107 26.5%  
Net fixed assets Rs m7,991128,806 6.2%   
Share capital Rs m23019,689 1.2%   
"Free" reserves Rs m19,7780-   
Net worth Rs m20,008276,768 7.2%   
Long term debt Rs m0413,464 0.0%   
Total assets Rs m27,7701,114,795 2.5%  
Interest coverage x468.83.9 11,935.5%   
Debt to equity ratio x01.5 0.0%  
Sales to assets ratio x0.90.5 179.6%   
Return on assets %11.88.2 144.2%  
Return on equity %16.324.2 67.2%  
Return on capital %25.813.6 189.2%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m1,0490-   
CASH FLOW
From Operations Rs m4,35173,187 5.9%  
From Investments Rs m-787-57,718 1.4%  
From Financial Activity Rs m-1,884-19,285 9.8%  
Net Cashflow Rs m1,680-3,815 -44.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 72.12 Rs / USD

Compare SANOFI INDIA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare SANOFI INDIA With: IPCA LABS  DISHMAN PHARMA  ALKEM LABORATORIES  FULFORD INDIA  NATCO PHARMA  



Today's Market

Sensex Ends 118 Points Higher; Realty and Banking Stocks Witness Buying(Closing)

Indian share markets continued to trade on a positive note during closing hours of trade and ended the day marginally higher.

Related Views On News

SANOFI INDIA Announces Quarterly Results (2QFY19); Net Profit Up 2.5% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, SANOFI INDIA has posted a net profit of Rs 1 bn (up 2.5% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Nov 15, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - STERLING BIOTECH COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS